Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".
ACS Chem Neurosci March 4, 2026 correction DOI: 10.1021/acschemneuro.6c00136 via PubMed Central
Summary
A correction notice clarifies that two errors in the original paper do not affect the accuracy of the results, interpretations, or conclusions. The first correction addresses a presentation issue in Table 1, confirming the data are correct. The second correction clarifies that thigmotaxis, a measure of anxiety-like behavior, was evaluated in rats given SDA or SDMA compounds. Compared to saline, only the 10 mg/kg dose of SDA significantly increased thigmotaxis, meaning the rats spent less time in the center of the arena.
Study at a glance
| Characteristics | Correction |
|---|---|
| Key finding | Only the 10 mg/kg dose of SDA, not SDMA, significantly increased thigmotaxis in rats. |
Abstract
Correction 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested doses of SDA and SDMA (2.5, 10, and 25 mg/kg) with saline (Figure 5B and 5E, respectively), a significant increase in thigmotaxis, reflected by reduced time spent in the center of the arena, was observed only for SDA at 10 mg/kg.